Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: “Window” Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)
JACC. Cardiovascular interventions | 8 Jan 2016
AJ Kirtane, PB Parikh, TD Stuckey, K Xu, B Witzenbichler, G Weisz, MJ Rinaldi, FJ Neumann, DC Metzger, TD Henry, DA Cox, PL Duffy, BR Brodie, EL Mazzaferri, R Parvataneni, A Maehara, P Généreux, R Mehran and GW Stone
This study sought to determine whether there is an ideal level of platelet reactivity (PR) to optimize safety and efficacy within the large multicenter ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents) study of 8,582 patients receiving successful drug-eluting stent implantation.
* Data courtesy of Altmetric.com